FutureChem Co.Ltd Net Assets
FutureChem Co.Ltd net assets. Based on the latest financial reports, FutureChem Co.Ltd (220100) has net assets worth ₩52.79 Billion KRW (≈ $35.78 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩69.72 Billion ≈ $47.25 Million USD) and total liabilities (₩16.93 Billion ≈ $11.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore FutureChem Co.Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩52.79 Billion |
| % of Total Assets | 75.72% |
| Annual Growth Rate | 6.34% |
| 5-Year Change | 4.01% |
| 10-Year Change | N/A |
| Growth Volatility | 95.31 |
Net Assets of FutureChem Co.Ltd (2016–2025)
Net assets of FutureChem Co.Ltd from 2016 to 2025. This chart illustrates how FutureChem Co.Ltd's net assets have evolved over time, based on quarterly financial data. See FutureChem Co.Ltd (220100) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for FutureChem Co.Ltd (2016–2025)
The table below shows the annual net assets of FutureChem Co.Ltd from 2016 to 2025. For live market cap and overall valuation, see how much is FutureChem Co.Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩54.83 Billion ≈ $37.16 Million |
+0.83% |
| 2024-12-31 | ₩54.38 Billion ≈ $36.85 Million |
-14.92% |
| 2023-12-31 | ₩63.91 Billion ≈ $43.31 Million |
-8.87% |
| 2022-12-31 | ₩70.14 Billion ≈ $47.53 Million |
+33.05% |
| 2021-12-31 | ₩52.72 Billion ≈ $35.72 Million |
+21.54% |
| 2020-12-31 | ₩43.37 Billion ≈ $29.39 Million |
+288.50% |
| 2019-12-31 | ₩11.16 Billion ≈ $7.57 Million |
-32.16% |
| 2018-12-31 | ₩16.46 Billion ≈ $11.15 Million |
-39.50% |
| 2017-12-31 | ₩27.20 Billion ≈ $18.43 Million |
-13.74% |
| 2016-12-31 | ₩31.53 Billion ≈ $21.37 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to FutureChem Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3303523483000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
FutureChem Co.Ltd Net Assets Breakdown (December 2025)
FutureChem Co.Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩144.34 Billion | 264.11% |
| Total Equity | ₩54.65 Billion | 100.00% |
FutureChem Co.Ltd Competitors by Market Cap
The table below lists competitors of FutureChem Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kervan Gıda Sanayi Ve Ticaret As
IS:KRVGD
|
$100.14 Million |
|
SINGULAR PEOPLE S EO-1
F:H0U
|
$100.16 Million |
|
SHANGHAI FUDAN H YC-,10
F:FDY
|
$100.17 Million |
|
Afyren SAS
PA:ALAFY
|
$100.18 Million |
|
Taiwan Takisawa Technology Co Ltd
TWO:6609
|
$100.10 Million |
|
Suzhou Shijing Environmental Technology Co.Ltd.
SHE:301030
|
$100.10 Million |
|
DIOSTECH Co.Ltd
KQ:196450
|
$100.10 Million |
|
Galleon Gold Corp
V:GGO
|
$100.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in FutureChem Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 54,379,648,010 to 54,650,415,280, a change of 270,767,270 (0.5%).
- Net loss of 11,251,212,300 reduced equity.
- Other factors increased equity by 11,521,979,570.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-11.25 Billion | -20.59% |
| Other Changes | ₩11.52 Billion | +21.08% |
| Total Change | ₩- | 0.50% |
Book Value vs Market Value Analysis
This analysis compares FutureChem Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.66x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.72x to 2.66x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩3841.87 | ₩6590.00 | x |
| 2017-12-31 | ₩3314.02 | ₩6590.00 | x |
| 2018-12-31 | ₩1960.55 | ₩6590.00 | x |
| 2019-12-31 | ₩1330.13 | ₩6590.00 | x |
| 2020-12-31 | ₩3186.16 | ₩6590.00 | x |
| 2021-12-31 | ₩2728.67 | ₩6590.00 | x |
| 2022-12-31 | ₩3173.99 | ₩6590.00 | x |
| 2023-12-31 | ₩2885.89 | ₩6590.00 | x |
| 2024-12-31 | ₩2460.96 | ₩6590.00 | x |
| 2025-12-31 | ₩2473.21 | ₩6590.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently FutureChem Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -60.26%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.36x
- Recent ROE (-20.59%) is above the historical average (-35.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -86.53% | -1678.83% | 0.05x | 1.05x | ₩-30.44 Billion |
| 2017 | -16.51% | -149.77% | 0.08x | 1.32x | ₩-7.21 Billion |
| 2018 | -72.73% | -212.38% | 0.09x | 3.89x | ₩-13.61 Billion |
| 2019 | -48.08% | -65.73% | 0.13x | 5.66x | ₩-6.48 Billion |
| 2020 | -53.26% | -209.76% | 0.13x | 1.90x | ₩-27.44 Billion |
| 2021 | -6.49% | -28.93% | 0.15x | 1.46x | ₩-8.69 Billion |
| 2022 | -19.90% | -111.02% | 0.14x | 1.26x | ₩-20.97 Billion |
| 2023 | -10.52% | -48.03% | 0.19x | 1.14x | ₩-13.09 Billion |
| 2024 | -17.32% | -54.46% | 0.23x | 1.37x | ₩-14.86 Billion |
| 2025 | -20.59% | -60.26% | 0.25x | 1.36x | ₩-16.72 Billion |
Industry Comparison
This section compares FutureChem Co.Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $490,498,627,337
- Average return on equity (ROE) among peers: 5.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| FutureChem Co.Ltd (220100) | ₩52.79 Billion | -86.53% | 0.32x | $100.14 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.62 Billion | 7.70% | 0.48x | $98.05 Million |
| Yuhan Corp. (000100) | $1.12 Trillion | 8.27% | 0.18x | $3.84 Billion |
| Yuhan Corp Preferred (000105) | $2.36 Trillion | 8.22% | 0.36x | $45.29 Million |
| Yuyu Pharma (000220) | $82.83 Billion | 5.48% | 0.47x | $40.03 Million |
| Yuyu Pharma Inc (000225) | $78.29 Billion | 7.52% | 0.42x | $13.08 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $32.56 Million |
| Ildong Holdings Co Ltd (000230) | $349.98 Billion | 5.99% | 1.02x | $43.17 Million |
| Samil Pharm (000520) | $70.03 Billion | 11.32% | 0.65x | $108.19 Million |
| Donga Socio Holdings (000640) | $306.84 Billion | 8.70% | 1.30x | $379.59 Million |
| Jw Pharmac (001060) | $230.09 Billion | -10.98% | 1.49x | $349.95 Million |
About FutureChem Co.Ltd
FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more